216 related articles for article (PubMed ID: 11375890)
1. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
[TBL] [Abstract][Full Text] [Related]
2. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer.
Salnikow K; Costa M; Figg WD; Blagosklonny MV
Cancer Res; 2000 Oct; 60(20):5630-4. PubMed ID: 11059752
[TBL] [Abstract][Full Text] [Related]
3. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
4. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
[TBL] [Abstract][Full Text] [Related]
5. Distinct promoter elements mediate the co-operative effect of Brn-3a and p53 on the p21 promoter and their antagonism on the Bax promoter.
Perez-Sanchez C; Budhram-Mahadeo VS; Latchman DS
Nucleic Acids Res; 2002 Nov; 30(22):4872-80. PubMed ID: 12433990
[TBL] [Abstract][Full Text] [Related]
6. p53 inhibits hypoxia-inducible factor-stimulated transcription.
Blagosklonny MV; An WG; Romanova LY; Trepel J; Fojo T; Neckers L
J Biol Chem; 1998 May; 273(20):11995-8. PubMed ID: 9575138
[TBL] [Abstract][Full Text] [Related]
7. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
Kaneuchi M; Yamashita T; Shindoh M; Segawa K; Takahashi S; Furuta I; Fujimoto S; Fujinaga K
Mol Carcinog; 1999 Sep; 26(1):44-52. PubMed ID: 10487521
[TBL] [Abstract][Full Text] [Related]
9. The chimeric E2A-HLF transcription factor abrogates p53-induced apoptosis in myeloid leukemia cells.
Altura RA; Inukai T; Ashmun RA; Zambetti GP; Roussel MF; Look AT
Blood; 1998 Aug; 92(4):1397-405. PubMed ID: 9694729
[TBL] [Abstract][Full Text] [Related]
10. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines.
Aurelio ON; Kong XT; Gupta S; Stanbridge EJ
Mol Cell Biol; 2000 Feb; 20(3):770-8. PubMed ID: 10629033
[TBL] [Abstract][Full Text] [Related]
11. A novel p53 mutant retained functional activity in lung carcinomas.
Ko JL; Chiao MC; Chang SL; Lin P; Lin JC; Sheu GT; Lee H
DNA Repair (Amst); 2002 Sep; 1(9):755-62. PubMed ID: 12509279
[TBL] [Abstract][Full Text] [Related]
12. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
13. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
[TBL] [Abstract][Full Text] [Related]
14. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
Kong XT; Gao H; Stanbridge EJ
J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
[TBL] [Abstract][Full Text] [Related]
16. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest.
Ryan KM; Vousden KH
Mol Cell Biol; 1998 Jul; 18(7):3692-8. PubMed ID: 9632751
[TBL] [Abstract][Full Text] [Related]
17. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
[TBL] [Abstract][Full Text] [Related]
19. Selective transcription of p53 target genes by zinc finger-p53 DNA binding domain chimeras.
Falke D; Fisher MH; Juliano RL
Biochim Biophys Acta; 2004 Nov; 1681(1):15-27. PubMed ID: 15566940
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
